AMLOGENYX
Live / Applied — First extension granted (statement of use) (as of 03 Oct 2025)
What this means for you
Not registered yet, but its 11 Sept 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98745195
- Mark type
- Stylized text
- Filed
- 11 Sept 2024
- Published for opposition
- 15 Apr 2025
- Attorney of record
- John Paul Oleksiuk
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neurological and genetic diseases and disorders; chemical, biological, and biochemical preparations for use in gene delivery technology for medical use, namely, nucleic acids in the nature of coding and noncoding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and regulatory sequences, for use in in vivo therapeutic use in gene therapy
Owner
- Amlogenyx Inc., Novato, CA, US
- Amlogenyx Inc., Novato, CA, US
Prosecution history
- 04 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Oct 2025 — SOU EXTENSION 1 GRANTED
- 03 Oct 2025 — SOU EXTENSION 1 FILED
- 03 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 10 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 15 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Apr 2025 — PUBLISHED FOR OPPOSITION
- 09 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 19 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 19 Mar 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 19 Mar 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 14 Mar 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 14 Mar 2025 — NON-FINAL ACTION E-MAILED
- 14 Mar 2025 — NON-FINAL ACTION WRITTEN